Overview
QNRX market data
Price History
QNRX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$14.80 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.48 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.25 – $41.80 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $8.4 · P/B 0.61.
Company News
Quoin Pharmaceuticals Receives FDA Clearance Of Its Investigational New Drug Application For QRX003 To Treat Peeling Skin SyndromeBenzinga · Jul 9, 2026, 12:40 PM
Quoin Pharmaceuticals Issued Notice Of Allowance From U.S. Patent And Trademark Office Titled Combination Treatment For Netherton SyndromeBenzinga · Jun 30, 2026, 12:35 PM
8-K filing — Quoin Pharmaceuticals, Ltd. (QNRX)SEC EDGAR · Jun 23, 2026, 8:15 PM
Quoin Pharmaceuticals Receives FDA's Conditional Approval For QYLEKI To Treat Netherton SyndromeBenzinga · Jun 23, 2026, 12:40 PM
Quoin Pharmaceuticals Establishes Japanese Subsidiary To Commercialize QRX003 For The Treatment Of Netherton Syndrome Upon Approval By AuthoritiesBenzinga · Jun 18, 2026, 12:45 PM
Quoin Pharmaceuticals Announces That Four Of Six Children In Its Ongoing Pediatric Netherton Syndrome Compassionate Use Study Were Classified As 'Improved' Or 'Significantly Improved' From Baseline Across Key Clinical EndpointsBenzinga · Jun 16, 2026, 12:40 PM
Quoin Pharmaceuticals QRX003 Receives Japan's Ministry Of Health, Labour And Welfare To Treat Netherton SyndromeBenzinga · Jun 4, 2026, 12:50 PM
Quoin Pharmaceuticals Pharmaceuticals Submits Investigational New Drug Application To FDA For Phase II Trial Of Peeling Skin Syndrome Treatment QRX003Benzinga · Jun 2, 2026, 12:36 PM